Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/30329% above fair value
$58.65+0.77 (+1.33%)
Close on Nov 18, 2026Market cap $3.00BP/E 139.6Yield –
Vericel net income
Net income is the profit left for shareholders after every expense, interest and tax.
Vericel's net income for the twelve months ending Jun 30, 2026 was $24.22M, up 240.8% year over year. For fiscal 2025 it was $16.52M, up 59.4% from the year before. The highest annual figure on record is $16.52M in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.52M | +59.4% |
| FY2024 | Dec 31, 2024 | $10.36M | – |
| FY2023 | Dec 31, 2023 | -$3.18M | – |
| FY2022 | Dec 31, 2022 | -$16.71M | – |
| FY2021 | Dec 31, 2021 | -$7.47M | -360.9% |
| FY2020 | Dec 31, 2020 | $2.86M | – |
| FY2019 | Dec 31, 2019 | -$9.67M | – |
| FY2018 | Dec 31, 2018 | -$8.14M | – |
| FY2017 | Dec 31, 2017 | -$17.29M | – |
| FY2016 | Dec 31, 2016 | -$19.57M | – |
| FY2015 | Dec 31, 2015 | -$16.34M | – |
| FY2014 | Dec 31, 2014 | -$19.92M | – |
| FY2013 | Dec 31, 2013 | -$15.62M | – |
| FY2012 | Dec 31, 2012 | -$29.47M | – |
| FY2010 | Jun 30, 2010 | -$14.56M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.21M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.30M | – |
| Q4 FY2025 | Dec 31, 2025 | $23.24M | +17.3% |
| Q3 FY2025 | Sep 30, 2025 | $5.07M | – |
| Q2 FY2025 | Jun 30, 2025 | -$553.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.25M | – |
| Q4 FY2024 | Dec 31, 2024 | $19.81M | +52.4% |
| Q3 FY2024 | Sep 30, 2024 | -$901.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.68M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.86M | – |
| Q4 FY2023 | Dec 31, 2023 | $12.99M | +119.4% |
| Q3 FY2023 | Sep 30, 2023 | -$3.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.02M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.50M | – |
| Q4 FY2022 | Dec 31, 2022 | $5.92M | +30.6% |
| Q3 FY2022 | Sep 30, 2022 | -$6.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.96M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.09M | – |
| Q4 FY2021 | Dec 31, 2021 | $4.54M | -62.9% |
| Q3 FY2021 | Sep 30, 2021 | -$4.93M | -236.3% |
| Q2 FY2021 | Jun 30, 2021 | -$3.79M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.29M | – |
| Q4 FY2020 | Dec 31, 2020 | $12.22M | +28.6% |
| Q3 FY2020 | Sep 30, 2020 | $3.62M | +4.3% |
| Q2 FY2020 | Jun 30, 2020 | -$8.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.71M | – |
| Q4 FY2019 | Dec 31, 2019 | $9.50M | +81.2% |
| Q3 FY2019 | Sep 30, 2019 | $3.47M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.79M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.84M | – |
| Q4 FY2018 | Dec 31, 2018 | $5.24M | +1726.5% |
| Q3 FY2018 | Sep 30, 2018 | -$1.07M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.65M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.66M | – |
| Q4 FY2017 | Dec 31, 2017 | $287.00K | 0.0% |
| Q3 FY2017 | Sep 30, 2017 | -$5.41M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.39M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.78M | – |
| Q4 FY2016 | Dec 31, 2016 | $287.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.68M | – |
See a number that looks wrong?